Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute, Atlanta, Ga.
Division of Cardiothoracic Surgery, New York Presbyterian Hospital-Columbia University Medical Center, New York, NY.
J Thorac Cardiovasc Surg. 2021 Mar;161(3):949-958.e4. doi: 10.1016/j.jtcvs.2020.11.169. Epub 2020 Dec 14.
We describe a novel, off-pump, epicardial implant that is intended to reshape both the mitral valve annulus and the left ventricle (LV) in those with secondary mitral regurgitation (MR).
Five patients underwent an epicardial implant with the Mitral Touch device (Mitre Medical Corp, Morgan Hill, Calif), during concomitant off-pump coronary artery bypass for secondary MR. The median age was 71.2 years; 4 patients had severe MR and 1 moderate. Patients were followed for 1 year with transthoracic echocardiography and computed tomography. Safety, cardiac remodeling, and MR were assessed by an independent core laboratory.
One patient died within 30 days from nondevice-related organ failure and the remaining 4 survived through 1-year follow-up. Implant technical success was 100% and took an average of 52 minutes. Paired computed tomography showed mean left ventricular end-systolic volume remodeling at 1 and 12 months of -35% and -31%, respectively. They averaged left atrial end-systolic volume remodeling of -12% and -15% at 1 and 12 months. Right ventricular end-systolic volume changes of -19% and -8% and right atrial end-systolic volume remodeling of -5% and 1%, at the 1- and 12-month time points were noted. Regurgitant volume by transthoracic echocardiography decreased by 46% and 44% and the ejection fraction from 34.6% to 32.1% and 39.5%, at 1 and 12 months, respectively. There were no device-related complications reported to 1 year.
The Epicardial Mitral Touch System for Mitral Regurgitation (ENRAPT-MR) study demonstrates a first-in-man, off-pump, epicardial repair of secondary MR. Procedural safety and geometric correction of the mitral valve apparatus and LV was achieved. Further studies in the United States are underway.
我们描述了一种新颖的、非体外循环的心脏外膜植入物,旨在重塑继发性二尖瓣反流(MR)患者的二尖瓣瓣环和左心室(LV)。
在因继发性 MR 而行非体外循环冠状动脉旁路移植术的同时,5 例患者接受了 Mitre Medical Corp(加利福尼亚州摩根山)的 Mitral Touch 装置心脏外膜植入。中位年龄为 71.2 岁;4 例为严重 MR,1 例为中度 MR。通过经胸超声心动图和计算机断层扫描对患者进行为期 1 年的随访。安全性、心脏重塑和 MR 由独立的核心实验室进行评估。
1 例患者在 30 天内死于与器械无关的器官衰竭,其余 4 例患者在 1 年随访期内存活。植入术技术成功率为 100%,平均用时 52 分钟。配对计算机断层扫描显示,左心室收缩末期容积重塑在 1 个月和 12 个月时分别为平均-35%和-31%。左心房收缩末期容积重塑在 1 个月和 12 个月时平均为-12%和-15%。在 1 个月和 12 个月时,右心室收缩末期容积变化分别为-19%和-8%,右心房收缩末期容积重塑分别为-5%和 1%。经胸超声心动图显示,反流容积减少了 46%和 44%,射血分数从 34.6%增加到 32.1%和 39.5%,分别在 1 个月和 12 个月时。截至 1 年时,未报告与器械相关的并发症。
Epicardial Mitral Touch System for Mitral Regurgitation(ENRAPT-MR)研究首次在人体中进行了非体外循环心脏外膜修复继发性 MR。实现了二尖瓣装置和 LV 的手术安全性和几何矫正。在美国正在进行进一步的研究。